Anti-NKG2DL gamma delta CAR-T cell therapy (Cytomed Therapeutics)

N/A

Report date: 2023/12/28 15:14:39

Base Information

Drug NameAnti-NKG2DL gamma delta CAR-T cell therapy (Cytomed Therapeutics)
Drug Alias NameCAR-grafted gamma delta T cell therapy (CytoMed)Haplo/ allogeneic NKG2DL-targetting chimeric antigen receptor-grafted γδ T cell therapy (Cytomed Therapeutics)Haploidentical/ allogeneic natural killer group 2D ligand CAR-γδT cell therapy (Cytomed Therapeutics)NKG2DL-targetting chimeric antigen receptor-grafted gamma delta T cell therapy (Cytomed Therapeutics)CTM-N2D
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-NKG2D ligands
TargetsNKG2D ligands
Therapy Area/IndicationsProstatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeMalaysia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCytomed Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesCytomed Therapeutics Pte Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsProstatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A